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The respiratory tract is the site of severe acute respiratory syn-drome coronavirus 2 (SARS-CoV-2) entry and infection; however, COVID-19 is a complex systemic disease, affecting 
the cardiovascular, renal, hematologic, gastrointestinal and central 
nervous systems1. As evidence emerges of predominantly lasting 
impairment of lung function related to fibrosis, more data on the 
long-term effects of COVID-19 on other organs are required2. A 
plethora of symptoms persist in patients surviving severe COVID-
19 (refs. 3,4), and a long COVID syndrome has been proposed5,6. 
However, the severity and duration of symptoms remain largely 
unknown. Chronic fatigue occurred after SARS infection in 2003 
(ref. 7), and it is well known in the aftermath of a spectrum of infec-
tious diseases8–13. Before the SARS-CoV-2 pandemic, patient man-
agement in intensive care was frequently associated with mental and 
physical decline, and this could partially explain long COVID in 
patients with severe illness14. However, the burden of long COVID 
in mild to moderately ill patients is not well defined. We assessed 
persistent symptoms 6 months after initial COVID-19 in a prospec-
tive cohort of hospitalized and home-isolated patients from the first 
pandemic wave in Bergen, Norway.
Results
All patients diagnosed at the only centralized testing facility in the 
city of Bergen were invited to participate, as well as all patients 
admitted to the city’s two hospitals: Haukeland University Hospital 
and Haraldsplass Deaconess Hospital. Recruitment commenced 
with the first diagnosed home-isolated and the first hospitalized 
patients; 92% of patients during the first pandemic wave agreed 
to participate. The objective was to identify factors and biomark-
ers associated with long-term complications. From 28 February 
to 4 April 2020, we consecutively recruited 357 patients who were 
positive for SARS-CoV-2. We collected demographic and clinical 
data as well as blood samples. Household members of patients who 
tested positive were included to ensure completeness of the cohort, 
and their infection was diagnosed by SARS-CoV-2-specific anti-
bodies at 2 months15. At 6-month follow-up, the study population 
available for analysis comprised 312 patients, of whom 247 were 
home-isolated and 65 were hospitalized (Fig. 1).
The median age of the study population was 46 years (inter-
quartile range (IQR) 30–58 years) with 51% (160/312) women. 
Forty-four percent had comorbidities (137/312), the most frequent 
being chronic lung disease (12%, 38/312, 34 with asthma), hyperten-
sion (11%, 35/312), chronic heart disease (7%, 22/312), rheumatic 
diseases (6%, 20/312), diabetes (4%, 13/312) and immunosuppres-
sive conditions (4%, 11/312). In 272 patients who recorded symp-
toms during acute disease, fatigue (90%, 244/272), cough (71%), 
headache (64%), myalgia (58%) and dyspnea (55%) were the most 
frequent, whereas only 21% had fever. Hospitalized patients were 
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Long-term complications after coronavirus disease 2019 (COVID-19) are common in hospitalized patients, but the spectrum 
of symptoms in milder cases needs further investigation. We conducted a long-term follow-up in a prospective cohort study 
of 312 patients—247 home-isolated and 65 hospitalized—comprising 82% of total cases in Bergen during the first pandemic 
wave in Norway. At 6 months, 61% (189/312) of all patients had persistent symptoms, which were independently associated 
with severity of initial illness, increased convalescent antibody titers and pre-existing chronic lung disease. We found that 52% 
(32/61) of home-isolated young adults, aged 16–30 years, had symptoms at 6 months, including loss of taste and/or smell 
(28%, 17/61), fatigue (21%, 13/61), dyspnea (13%, 8/61), impaired concentration (13%, 8/61) and memory problems (11%, 
7/61). Our findings that young, home-isolated adults with mild COVID-19 are at risk of long-lasting dyspnea and cognitive 
symptoms highlight the importance of infection control measures, such as vaccination.
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older than home-isolated patients, had higher body mass index 
(BMI) and had more comorbidities, including chronic lung disease, 
chronic heart disease, hypertension and diabetes (Table 1).
Sixty-one percent (189/312) of the total patient population had 
persistent symptoms 6 months after initial COVID-19 illness, with 
the most common symptoms being fatigue (37%), difficulty concen-
trating (26%), disturbed smell and/or taste (25%), memory problems 
(24%) and dyspnea (21%). Whereas the frequency of most symp-
toms increased with age in the study population, disturbed smell 
and/or taste was more frequent in people younger than 46 years old 
(Table 2). Thirty-nine percent of the study population, commonly 
children and young adults, had no symptoms at 6 months. Even 
among the 247 home-isolated patients, 55% (136/247) experienced 
persistent symptoms at 6 months, most commonly fatigue (30%), 
disturbed taste and/or smell (27%), concentration impairment 
(19%), memory loss (18%) and dyspnea (15%) (Table 2).
The youngest age group (0–15 years) rarely suffered persis-
tent symptoms (13%, 2/16), whereas 52% (32/61) of young adults 
aged 16–30 years who were home-isolated for mild to moderate 
initial illness had persistent symptoms, the most common being 
disturbed taste and/or smell (28%), fatigue (21%), dyspnea (13%) 
and impaired concentration (13%) and memory (11%) (Table 2). 
In these young adults, comorbidity was not significantly associated 
with persistent symptoms (33% versus 31%, P = 1) or fatigue (47% 
versus 27%, P = 0.2), although numbers of subjects were low.
Convalescent antibodies reach a plateau approximately 1–2 
months after infection, providing a general marker for the magni-
tude of the immune response16. SARS-CoV-2 spike protein specific 
IgG and microneutralizing antibody titers detected after 2 months 
were significantly higher in hospitalized patients than home-isolated 
patients (P < 0.001; Extended Data Fig. 1). Increased antibody titers 
at 2 months were associated with the severity of initial illness, older 
age and higher BMI in multivariable analysis (Table 3 and Fig. 2; 
severity score adapted from Beigel et al.17).
Increased antibody titers as well as pre-existing lung disease 
were independently associated with both persistent fatigue and total 
number of symptoms at 6 months in multivariable analysis (Table 4 
and Fig. 2c,d,g,h). Severity of initial illness was associated with per-
sistent fatigue and weakly associated with total number of symp-
toms (Table 4).
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Fig. 1 | Study population flow chart. Number of participants eligible for inclusion at baseline, blood sampling at 2 months and assessment and fatigue 
evaluation at 6 months. BMEC, Bergen Municipality Emergency Clinic; LTF, lost to follow-up.
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Post-viral fatigue has been reported afer SARS infection7 and 
other viral infections11–13. To assess fatigue, we used the Chalder 
fatigue score, which is validated for adults18,19. Fatigue is defined as 
a total bimodal score of 4 or higher on 11 questions. Thirty per-
cent (69/231) of home-isolated patients, 16 years of age or older, 
had fatigue at 6 months compared to 63% (39/62) of hospitalized 
patients. Severe fatigue at 6 months, defined as bimodal score ≥4 + 
total ordinal score ≥23, was present in 7% (17/231) of home-isolated 
and 24% (15/62) of hospitalized patients (Supplementary Table 1). 
In home-isolated patients, the most frequent symptoms of physi-
cal fatigue (questions 1–7) were tiredness (35%, 81/231), increased 
need for rest (30%) and lack of energy (29%); the most common 
symptoms of mental fatigue (questions 8–11) were difficulties find-
ing words (23%), difficulties concentrating (19%) and memory 
problems (18%) (Supplementary Table 1).
In patients 16 years of age or older, fever during acute illness, 
severity of initial illness and female gender were associated with 
fatigue at 6 months in binomial logistic regression (Supplementary 
Table 2). In addition to female gender, pre-existing lung disease, 
severity of acute illness and increased convalescent antibody titers 
were independently associated with increasing fatigue score at 6 
months in multivariable analysis (Table 4 and Fig. 2d,h).
Despite the correlation between severity of initial disease and 
antibody titers at 2 months, both factors were independently 
associated with features of long COVID in multivariable analysis 
(Table 4 and Supplementary Table 2). In stratified analysis of 242 
home-isolated patients with low to moderate symptoms, increased 
antibody titers remained associated with number of symptoms 
(odds ratio (OR) = 1.56, confidence interval (CI) 1.23–1.96) and 
fatigue score (OR = 1.07, CI 1.02–1.12), although the association 
Table 1 | Characteristics of study population available for follow-up at 6 months
Seronegative exposed 
controls






% (n) % (n) % (n) % (n)
N = 60 N = 312 N = 65 N = 247
Female sex 63% (38) 51% (160) 46% (30) 53% (130)
Age, median (IQR) 29 (14–48) 46 (30–58) 55 (45–68) 43 (27–55)
Age categories
 0–15 years 28% (17) 5% (16) 0% (0) 6% (16)
 16–30 years 23% (14) 21% (65) 6% (4) 25% (61)
 31–45 years 22% (13) 22% (69) 17% (11) 23% (58)
 46–60 years 25% (15) 29% (90) 35% (23) 27% (67)
 >60 years 2% (1) 23% (72) 42% (27) 18% (45)
BMI, median (IQR) 23.3 (20.9–25.6) 24.6 (22.8–27.3) 27.0 (24.1–29.9) 24.3 (22.5–26.5)
Any comorbiditya 15% (9) 44% (137) 69% (45) 37% (92)
 Asthma, COPDb 2% (1) 12% (38) 22% (14) 10% (24)
 Hypertension 0% (0) 11% (35) 25% (16) 8% (19)
 Chronic heart disease 0% (0) 7% (22) 18% (12) 4% (10)
 Rheumatic disease 2% (1) 6% (20) 12% (8) 5% (12)
 Diabetes mellitus 3% (2) 4% (13) 9% (6) 3% (7)
 Immunosuppression 0% (0) 4% (11) 8% (5) 2% (6)
Current or prior smokerc 19% (11/57) 31% (96/310) 39% (25/64) 29% (71/246)
Severity of diseased
 Asymptomatic (1) 53% (30/57)e 2% (5/312) - 2% (5/247)
 Home-isolated with symptoms (2) 47% (27/57)e 78% (242/312) - 98% (242/247)
 Hospitalized without medical needs (3) - - -
 Hospitalized with medical needs (4) 10% (31/312) 48% (31/65) -
 Hospitalized needing O2 (5) 8% (24/312) 37% (24/65) -
 Hospitalized needing NIV (6) 1% (4/312) 6% (4/65) -
 Hospitalized needing respirator (7) 2% (6/312) 9% (6/65) -
 Dead (8) - - -
Severity of illness, median (IQR) - 2 (2–2) 5 (4–5) 2 (2–2)
Days in hospital, median (IQR) - 0 (0–0) 6 (2–8) 0 (0–0)
Spike antibodiesf Negativeg 3.9 (3.8–4.0) 4.6 (4.4–4.8) 3.7 (3.6–3.8)
Microneutralizing antibodiesf - 2.0 (2.0–2.1) 2.9 (2.7–3.1) 1.8 (1.8–1.9)
COPD, chronic obstructive pulmonary disease; O2, supplemental oxygen; NIV, non-invasive ventilation. aComorbidities are listed in descending order of frequency. Participants were asked if they had 
any comorbidities; if yes, they were asked about the following specific comorbidities: asthma, chronic obstructive lung disease, chronic heart disease, hypertension, chronic liver disease, kidney disease, 
neuromuscular disease, dementia, rheumatic disease, active cancer, other severe chronic disease and immunosuppressive conditions, including genetic immunodeficiency, HIV, organ transplant and 
cytostatic or other immunosuppressive treatment. b34 of 38 had asthma. cNot known for five patients. dEight-step severity score modified after Beigel et al. (ref. 17). eMissing data for three patients. 
fMeasured 2 months after initial illness; log10 titers of IgG antibodies, means and 95% confidence intervals. gBelow the assay detection limit; only positive samples were run in the microneutralization assay.
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Table 2 | Long-term complications by age group in 247 home-isolated patients with COVID-19 at 6-month follow-up
Characteristic All 0–15 years 16–30 years 31–45 years 46–60 years Over 60 years
% (n/N) % (n) % (n) % (n) % (n) % (n)
N = 247 N = 16 N = 61 N = 58 N = 67 N = 45
Age, median (IQR) 43 (27–55) 8 (6–12) 24(22–27) 37 (34–41) 53 (49–55) 67 (63–73)
Female gender 53% (131/247) 56% (9) 54% (33) 52% (30) 52% (35) 53% (24)
Status at 6 months
Any symptoms 55% (136/247) 13% (2)* 52% (32) 59% (34) 61% (41) 60% (27)
Fever 2% (4/247) 0% (0) 0% (0) 5% (3) 1% (1) 0% (0)
Cough 6% (15/247) 0% (0) 0% (0) 9% (5) 4% (3) 16% (7)
Dyspnea 15% (38/247) 0% (0) 13% (8) 17% (10) 18% (12) 18% (8)
Palpitations 6% (15/247) 0% (0) 3% (2) 7% (4) 9% (6) 7% (3)
Stomach upset 6% (15/247) 6% (1) 5% (3) 7% (4) 6% (4) 7% (3)
Disturbed taste/smell 27% (67/247) 13% (2) 28% (17) 34% (20) 28% (19) 20% (9)
Fatigue 30% (69/231) - a 21% (13) 31% (18) 33% (22) 36% (16)
Concentration problems 19% (44/231) - a 13% (8) 19% (11) 21% (14) 24% (11)
Memory problems 18% (42/231) - a 11% (7) 16% (9) 22% (15) 24% (11)
Sleep problems 5% (13/247) 0% (0) 5% (3) 7% (4) 4% (3) 7% (3)
Headache 11% (28/247) 0% (0) 11% (7) 14% (8) 9% (6) 16% (7)
Dizziness 10% (24/247) 0% (0) 7% (4) 10% (6) 10% (7) 16% (7)
Tingling in fingers 4% (9/247) 0% (0) 0% (0) 2% (1) 4% (3) 11% (5)
*Statistically significant difference at level P < 0.05 in univariable analysis using binomial logistic regression with age group 46–60 as reference group. aChildren younger than 16 years were not assessed for 
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Fig. 2 | Six-month follow-up of patients with COVID-19 in Bergen, Norway. The relationship of severity of initial COVID-19 illness and of age with 
anti-SARS-CoV-2 spike (a and b) and microneutralizing antibody titers (e and f) at 2 months. The relationship of antibody titers at 2 months with number 
of persistent symptoms (c and g) and total fatigue score according to the Chalder scale (d and h) at 6-month follow-up. The 13 symptoms used are listed 
in Table 2. The severity of illness was as follows: 1—asymptomatic (n = 5); 2—home-isolated with symptoms (n = 242); 3—hospitalized without medical 
needs (n = 0); 4—hospitalized with medical needs (n = 31); 5—hospitalized needing O2 (n = 24); 6—hospitalized needing non-invasive ventilation (n = 4); 
and 7—hospitalized needing respirator (n = 6). The cohort was divided into 15-year age groups: 0–15 (n = 16), 16–30 (n = 65), 31–45 (n = 69), 46–60 
(n = 90) and >60 (n = 72). a, b, e and f show median spike IgG and microneutralizing antibody titers (horizontal line), 25% and 75% quantiles (box), plus 
95% confidence intervals (lines) with outliers (dots). c and d are violin plots of number of symptoms (up to 13) or fatigue score (values 0–33) divided into 
four categories of spike IgG: <150 (n = 21), 150–4999 (n = 96), 5,000–20,000 (n = 103) and >20,000 (n = 92). 5k, 5,000; 20k, 20,000. g and h are violin 
plots of four categories of microneutralizing titers: <20 (neg n = 42), 20–79 (n = 107), 80–320 (n = 92) and >320 (n = 71). O2, supplemental oxygen.
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Table 3 | Factors associated with increasing convalescent antibody titers in COVID-19
Geometric mean ratio (CI) P
n (%) unadjusted Adjusted
Total 312 (100%)
Female sex 160 (51%) 0.63 (0.41–0.97) 0.036 0.81 (0.56–1.18) 0.276
Older age (by 10-year intervals) 1.50 (1.35–1.67) <0.001 1.23 (1.09–1.38) <0.001
BMI 1.17 (1.12–1.23) <0.001 1.05 (1.00–1.11) 0.035
Comorbidity
 Asthma/COPD 38 (12%) 1.70 (0.88–3.28) 0.111
 Hypertension 35 (11%) 5.43 (2.82–10.46) <0.001 1.74 (0.89–3.43) 0.108
 Chronic heart disease 22 (7%) 4.68 (2.06–10.64) <0.001 0.94 (0.41–2.16) 0.891
 Rheumatic disease 20 (6%) 1.67 (0.70–4.01) 0.249
 Diabetes 13 (4%) 3.57 (1.23–10.37) 0.020 1.47 (0.59–3.71) 0.409
 Immunosuppression 11 (4%) 1.51 (0.47–4.83) 0.488
Current or prior smoker 96 (31%) 1.57 (0.99–2.50) 0.055
Severity of initial illness 2.12 (1.82–2.48) <0.001 1.67 (1.34–2.07) <0.001
Days in hospital 1.10 (1.07–1.13) <0.001 1.01 (0.97–1.04) 0.679
Associated factors were analyzed by linear regression with log-transformed antibody titers as response variables and reported as geometric mean ratios with 95% confidence intervals (CIs) and P values. 
Factors with significance level P < 0.1 in univariable analysis were included in the multivariable analyses. For factors with significance level P < 0.05, the P values are shown in bold.
Table 4 | COVID-19 patient factors associated with increasing number of symptoms and higher fatigue score at 6-month follow- 
up—negative binomial regression analysis
Number of symptoms (0–13)a Fatigue score (0–33)b
n (%) RR (CI) Pc aRR (CI) Pd n (%)b RR (CI) Pc aRR (CI) Pd
N = 312 N = 293
Female sex 160 (51%) 1.28 (0.95–1.73) 0.101 1.35 (1.01–1.81) 0.040 149 (51%) 1.09 (1.01–1.16) 0.018 1.09 (1.02–1.16) 0.014
Older age (by 
10-year intervals)
1.18 (1.06–1.28) <0.001 1.08 (0.98–1.19) 0.092 1.03 (1.01–1.05) 0.002 1.00 (0.98–1.02) 0.924
BMI 1.04 (1.01–1.08) 0.016 1.00 (0.97–1.04) 0.876 1.01 (1.00–1.02) 0.048 1.00 (0.99–1.01) 0.715
Comorbidity
 Asthma/COPD 38 (12%) 2.00 (1.33–3.07) 0.001 1.57 (1.05–2.37) 0.031 37 (13%) 1.22 (1.11–1.34) <0.001 1.14 (1.03–1.25) 0.008
 Hypertension 35 (11%) 1.44 (0.93–2.30) 0.114 34 (12%) 1.13 (1.02–1.26) 0.017 1.01 (0.90–1.13) 0.902
 Chronic heart 
disease
22 (7%) 1.70 (1.01–3.02) 0.057 1.23 (0.71–2.18) 0.460 21 (7%) 1.20 (1.06–1.35) 0.005 1.08 (0.94–1.23) 0.295
 Rheumatic disease 20 (6%) 1.35 (0.77–2.50) 0.321 20 (7%) 1.15 (1.01–1.30) 0.038 1.05 (0.92–1.18) 0.460
 Diabetes 13 (4%) 1.33 (0.67–2.87) 0.438 13 (4%) 1.14 (0.97–1.34) 0.098 1.06 (0.91–1.23) 0.445
 Immunosuppression 11 (4%) 1.18 (0.56–2.76) 0.679 10 (3%) 1.12 (0.93–1.34) 0.232
Current or prior 
smoker
96 (31%) 1.18 (0.86–1.63) 0.305 95 (32%) 1.05 (0.97–1.12) 0.230
Severity of initial 
illness
1.28 (1.14–1.44) <0.001 1.17 (1.00–1.37) 0.062 1.08 (1.05–1.10) <0.001 1.06 (1.02–1.10) 0.004
Days in hospital 1.02 (1.00–1.05) 1.016 0.99 (0.97–1.02) 0.525 1.01 (1.00–1.01) 0.002 1.00 (0.99–1.00) 0.464
Spike IgG titer at 2 
monthse
1.51 (1.26–1.81) <0.001 1.25 (1.01–1.56) 0.037 1.11 (1.07–1.16) <0.001 1.07 (1.02–1.12) 0.009
Microneutralizing 
antibody titer at 2 
monthse
1.52 (1.25–1.86) <0.001 -f 1.13 (1.08–1.19) <0.001 -f
Analysis of associated factors was done by negative binomial regression. aRR, adjusted rate ratio; RR, rate ratio. Statistical significance at the level of P < 0.05 is shown in bold text. aPatients were assessed 
for 13 symptoms mentioned in Table 2. bChalder fatigue score is validated only for patients aged ≥16 years (n = 293); possible fatigue scores range from 0 (no fatigue) to 33 (worst possible fatigue). 
cNeurological illness (n = 8) and malignancy (n = 5) were not significantly associated with the outcomes and were not included in the table. dFactors with statistical significance of <0.1 were included in the 
multivariable analysis. eSARS-CoV-2 spike protein antibody titers, log10 transformed. fMicroneutralizing antibody titers were omitted owing to collinearity with spike IgG antibody titers.
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was not statistically significant for fatigue as a dichotomous variable 
(OR = 1.48, CI 0.98–2.31).
Discussion
Our study is novel in assessing long COVID symptoms, not 
only in hospitalized patients but also in young patients and 
home-isolated patients with milder disease. A strength is a 
near-complete, geographically defined cohort of both antibody- and 
reverse-transcriptase polymerase chain reaction (RT-PCR)-positive 
patients from the first pandemic wave, including all severities of dis-
ease, in an immunologically naive population. The small subgroups 
are a limitation of this study, and our findings should be confirmed 
in larger cohorts.
We found that a large proportion of survivors of COVID-19 in 
our cohort had persistent symptoms 6 months after their initial 
illness. Although it has previously been reported that patients hos-
pitalized for severe COVID-19 frequently suffer long-term symp-
toms20–23, we found that more than half of home-isolated, mildly 
to moderately ill patients with COVID-19 still suffered symptoms 
6 months after infection. It is worrying that non-hospitalized, 
young people (16–30 years old) suffer potentially severe symp-
toms, such as concentration and memory problems, dyspnea 
and fatigue, half a year after infection. Particularly for students, 
such symptoms might interfere with their learning and study 
progress.
The high prevalence of persistent fatigue in patients with 
COVID-19 is striking and appears higher than observed after com-
mon infections, such as influenza, Epstein–Barr virus mononu-
cleosis and dengue11–13. Data from Norway have previously shown 
slightly lower chronic fatigue prevalence (11%) in the general pop-
ulation24 than in the present household controls (14%), who were 
younger and had fewer comorbidities than infected patients but 
were sampled at the same time. However, this apparent difference 
might be a coincidence owing to low numbers. Our finding that 
women had higher prevalence of fatigue concurs with results from 
an earlier study in the general Norwegian population24. The asso-
ciation between severity of illness and persistent symptoms agrees 
with data from hospitalized patients with COVID-19 (ref. 20). As 
the respiratory tract is the main target organ for COVID-19, our 
finding of an association between underlying chronic lung disease 
(mostly asthma) and persistent symptoms, including fatigue, is not 
surprising.
The association between severe initial disease and increased 
antibody titers at 2 months could be due to higher viral load, which 
could trigger the immune system more profoundly25. The finding of 
increased convalescent antibody titers with increasing age could be 
explained by more severe disease in older people, as age is a known 
strong risk factor for severe COVID-19. However, by contrast with 
the immunosenescence observed after influenza infection in the 
elderly, multivariable analysis indicated that age and severity of ill-
ness were independently associated with increased antibody titers. 
These findings call for enhanced surveillance of COVID-19 mass 
vaccination programs. Home-isolated patients aged 16–30 years 
with mild COVID-19 are at risk of long-lasting dyspnea and cogni-
tive symptoms. Considering the millions of young people infected 
during the ongoing pandemic, our findings are a strong impetus 
for comprehensive infection control and population-wide mass 
vaccination.
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Methods
Ethical considerations. All participants, or their guardians for children younger 
than 16 years old, provided written informed consent. The study was approved by 
the Regional Ethics Committee of Western Norway (no. 118664). No compensation 
was provided to participants beyond reimbursing travel costs to the clinic.
Study population. As part of a prospective cohort study with long-term 
follow-up, we consecutively enrolled home-isolated patients diagnosed with 
COVID-19 in the period 28 February to 4 April 2020, during the first wave of 
the pandemic in Bergen, Norway. For hospitalized patients, we accepted longer 
inclusion due to delay in hospitalization, up to 6 May. The study population 
included SARS-CoV-2 RT–PCR-positive patients diagnosed at Bergen 
Municipality Emergency Clinic and those admitted to the two neighboring 
city hospitals: Haukeland University Hospital and Haraldsplass Deaconess 
Hospital. Household contacts of identified patients were invited to participate 
in the study as secondary cases (seroconverters) or seronegative controls15. All 
registered patients with SARS-CoV-2 were invited to participate. The initial rate of 
participation at inclusion was 92% (278/302); at 2 months, the rate of participation 
was 88% (336/381, numerator and denominator includes seropositive household 
members at this time point); and at 6 months, the rate of participation was 82% 
(312/381). Convalescent serum samples were collected 2 months after infection 
for detection of anti-SARS-CoV-2 antibody titers.
All testing in Bergen was centralized to the Emergency Clinic and the city’s two 
hospitals, allowing recruitment of all consenting patients diagnosed with COVID-
19 in Bergen. In total, 3,319 patients were tested by RT–PCR in the Municipality 
Emergency Clinic during the period. Of these, 228 tested positive by RT-PCR, 
and six were excluded because their address was outside of Bergen or because 
they were admitted to hospital and were categorized as hospitalized. All suspected 
cases seen at the Municipality Emergency Clinic were examined clinically and 
diagnosed by medical staff. Patients with moderate disease were sent home for 
home isolation, or, if considered severe, they were hospitalized. Most of the 
hospitalized patients were diagnosed upon admission. Nasopharyngeal swabs were 
collected for laboratory confirmation. Patients were telephoned with their results 
of the RT–PCR test, which was conducted at the reference microbiology laboratory 
in the tertiary hospital. All confirmed home-isolated patients were contacted by 
telephone with an invitation to join the study. An additional 79 patients were 
identified through investigation of seroconversion of household members of  
RT–PCR-positive patients. Telephone interviews were conducted by medical staff 
to collect clinical and demographic data. Participants attended the University 
Clinic at 2 months (6–8 weeks) and 6 months (±1 month) for follow-up 
appointments with medical staff where they were interviewed about long-term 
symptoms.
Clinical data. All consenting patients attended a follow-up clinic and were 
interviewed by medical staff at baseline, 2 months and 6 months. They provided 
demographic information; clinical information on symptoms at baseline 
and 6-month follow-up; and information on potential risk factors, including 
comorbidities and use of medication. Specific symptoms recorded during acute 
illness included fever, cough, dyspnea, fatigue, myalgia and headache. Participants 
were asked if they had any comorbidities and, if so, which specific comorbidities 
from the following: asthma, chronic obstructive lung disease, chronic heart 
disease, hypertension, chronic liver disease, kidney disease, neuromuscular 
disease, dementia, rheumatic disease, active cancer, other severe chronic disease 
and immunosuppressive conditions, including genetic immunodeficiency, HIV, 
organ transplant, and cytostatic or other immunosuppressive treatment. Data 
were collected on severity of initial illness—that is, need for hospitalization, 
symptoms during acute illness and need for non-invasive ventilatory support 
or respirator treatment17. Radiological investigations were conducted only on 
hospitalized patients. At 6-month follow-up, all participants aged 16 years or 
older were invited to complete a validated fatigue questionnaire containing 11 key 
questions according to the Chalder fatigue scale18,19. Fatigue was defined as a total 
dichotomized score of 4 or higher. Severe fatigue was defined as fatigue plus a total 
Chalder score of 23 or higher.
Laboratory methods. Diagnosis of COVID-19 was based on RT–PCR on samples 
from nasopharyngeal swabs and on serological evidence of SARS-CoV-2 antibody 
positivity26. Serum samples were collected 2 months after infection for detection 
of anti-SARS-CoV-2 antibody titers and stored at −80 °C until analyzed. Samples 
were heat-inactivated for 1 h at 56 °C before analysis in duplicate by a two-step 
ELISA for detecting SARS-CoV-2-specific IgG antibodies (Southern Biotech, cat. 
no. 2040-05) to the receptor-binding domain (RBD) (screening 1:100 dilution) 
and the spike protein (confirmation from 1:100 in five-fold dilutions). Endpoint 
titers were calculated as the reciprocal of the serum dilution giving an optical 
density value of 3 standard deviations above the mean of historical pre-pandemic 
serum samples (n = 128)26. Sera with antibodies against the RBD were tested in a 
microneutralization assay using the local isolate hCoV-19/Norway/Bergen-01/2020 
(GISAID accession ID EPI_ISL_541970) in a certified Biosafety Level 3 laboratory 
as previously described27. Briefly, sera were tested in duplicate in doubling dilutions 
starting from 1:20 dilution and mixed with 100 TCID50 viruses, followed by 
incubation with rabbit monoclonal IgG against SARS-CoV2 NP (Sino Biological, 
cat. no. 40143-R019-100) and biotinylated goat anti-rabbit IgG (H+L) (Southern 
Biotech, cat. no. 4050-08) and extravidin–peroxidase (Sigma-Aldrich, cat. no. 
E2886). The microneutralizing antibody titer is the reciprocal of the serum dilution 
giving 50% inhibition of virus infectivity. For all control individuals, negative 
serology was confirmed at 6 months.
Statistical analysis. Data were entered using electronic case report forms 
in REDCap (Research Electronic Data Capture, Vanderbilt University). All 
analyses were conducted in R version 4.0.3 (www.r-project.org), and graphs were 
produced in R using the ggplot and gridExtra packages. Patients who responded 
to the questionnaire were included in the analysis, and results are presented 
as percentages with means or medians and 95% CIs. In univariable analysis, 
categorical variables were compared using the chi-square test and binomial logistic 
regression and presented with ORs, 95% CIs and P values.
Multivariable analysis was performed by binary logistic regression for 
dichotomous outcome variables (Supplementary Tables 1 and 2). We used 
negative binomial regression employing the MASS package in R to analyze 
factors associated with numeric outcome variables (Table 4)—that is, ‘number 
of symptoms’, encoded as integers from 0 to 13, according to symptoms listed 
in Table 2, and fatigue score according to the Chalder scale encompassing 
values from 0 to 33. For convalescent antibody titer as outcome variable, we 
log-transformed the titer values to obtain near-normal distribution and performed 
linear regression and reported results as unadjusted and adjusted geometric 
mean ratios for univariable and multivariable analysis, respectively (Table 3). In 
Tables 3 and 4, we included a priori potential risk factors of interest but omitted 
rare occurrences, and, for multivariable analysis, we included gender as well as 
variables that had a significance level of P < 0.1 in univariable analysis. Owing to 
strong collinearity between spike IgG and microneutralizing antibody titers, and 
because microneutralizing antibodies are a proportion of total IgG, we omitted 
microneutralizing antibodies from the multivariable analysis.
The analysis focuses on the potential effect of antibody titers as an exposure 
variable on fatigue and symptom score, respectively, as outcome variables. We 
assessed the confounding and effect size modification of all other exposure factors 
that were significant in univariable analysis.
Severity of illness was classified using an eight-category ordinal scale, as 
previously published17. The categories are as follows: 1—not hospitalized and no 
limitations of activities; 2—not hospitalized, with limitation of activities, home 
oxygen requirement or both; 3—hospitalized, not requiring supplemental oxygen 
and no longer requiring ongoing medical care (used if hospitalization was extended 
for infection control or other non-medical reasons); 4—hospitalized, not requiring 
supplemental oxygen but requiring ongoing medical care (related to COVID-19 
or to other medical conditions); 5—hospitalized, requiring any supplemental 
oxygen; 6—hospitalized, requiring non-invasive ventilation or use of high-flow 
oxygen devices; 7—hospitalized, receiving invasive mechanical ventilation or 
extracorporeal membrane oxygenation; and 8—death.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Small subgroups of patients make the risk of identification of sensitive data of 
individual patients possible; therefore, the data are not openly accessible.
Code availability
The R code used to generate all results in this paper is publicly available on GitHub 
(https://github.com/BC19RG/NatureMedicine2021).
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Extended Data Fig. 1 | Correlations between severity of acute illness, antibody titres at 2 months and number of symptoms at 6 months follow-up. Panel 
a is a scatter plot showing the correlation between severity of initial illness and the Spike IgG antibody titres (log 10) at 2 months follow-up. Panel b shows 
the correlation between Spike IgG antibody titres (log 10) at 2 months follow-up and the number of symptoms at 6 months follow-up, stratified by severity 
of initial illness, that is home-isolated versus hospitalised patients. A regression line calculated by linear model is shown in each graph with standard error 
represented by the shaded area.
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